DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Cresanto Global Limited (RAYMEDLABSLTD) share price today?

Cresanto Global Limited (RAYMEDLABSLTD) is trading at ₹4.88 on the NSE, up 0.00% on the day. Source: DocStoX.

What is the market capitalisation of Cresanto Global Limited?

Cresanto Global Limited has a market capitalisation of approximately ₹2 crore.

Cresanto Global Limited

RAYMEDLABSLTD·NSE·Healthcare

₹4.88▲ +0.00 (+0.00%)

⚠️Trading suspended — last traded ₹4.88 on 6 Jul 2026 (12 days ago). Not a live price.

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Open

₹4.88

High

₹4.88

Low

₹4.88

Prev Close

₹4.88

Volume

VWAP

₹4.80

Snapshot

Key fundamentals

Market Cap

₹2 Cr

P/E Ratio

N/A

P/B Ratio

-0.69

EPS

₹-0.42

Book Value

N/A

ROE

6.97%Weak

ROCE

30.27%Efficient

Dividend Yield

0.00%

Debt / Equity

0.00Low

Face Value

₹10.00

52W High

₹4.88

52W Low

₹4.88

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Fairly Valued

None moatHigh uncertainty

Fair value unavailable

/100

Business quality — Solid

Growth 50Profitability 5Efficiency 100Valuation 100

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Weak returns on equity (7%)

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 30%)

Risks

Weak returns on equity (7%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

7.0%Weak

Above 15% is considered healthy for Indian equities

ROCE

30.3%Efficient

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹2 Cr

P/B

-0.69

EPS

₹-0.42

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

N/A

No history

Profitability

Modest

7.0% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹48 Cr

Trades2

VWAP₹4.80

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

No growth history

Not enough annual history to compute CAGR.

Profile

Cons

Company has low interest coverage ratio.
Promoter holding is low: 32.3%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

32%

Promoter

Promoters

32.3%0.00

Public

44.1%-0.04

FII / FPI

0.0%0.00

DII

1.0%0.00

Others

22.7%

Total shareholders

1,481-1 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter32.27%

DII0.96%

Public44.11%

Others22.66%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1994, Raymed Labs Ltd is in the business of providing ophthalmological products[1]